

R 817 E601
BWT

36974

8201858

Clinical Use of Radioisotopes



WILLIAM H. BEIERWALTES, M.D.

Associate Professor of Internal Medicine and Coordinator, Clinical Radioisotope Unit, University Hospital, Ann Arbor

PHILIP C. JOHNSON, M.D.

Assistant Professor of Internal Medicine and Chief, Radioisotope Unit, Veterans Administration Hospital, University of Oklahoma Medical School, Oklahoma City

ARTHUR J. SOLARI, B.S., M.S. (Physics)

Instructor in Radiation Physics, Department of Radiology, Radiation Physicist for Clinical Radioisotope Unit and Kresge Research Isotope Unit, University Hospital, Ann Arbor

Illustrated

W. B. SAUNDERS COMPANY

Philadelphia

1957

London

40002

© 1957, by W. B. Saunders Company

Copyright under the International Copyright Union

All Rights Reserved. This book is protected by copyright. No part of it may be duplicated or reproduced in any manner without written permission from the publisher. *Made in the United States of America.* Press of W. B. Saunders Company. Library of Congress Catalog Card Number: 56-10933

Preface



THIS TEXT for the clinician was originally conceived as a means of reducing the load of repetitive teaching that we have carried in the Clinical Radioisotope Unit, University Hospital, since 1947. Our first students were technicians. Then the departments of radiology, medicine and surgery made the Clinical Radioisotope Unit a regular rotation for every resident in these departments. In addition, many residents in pediatrics, obstetrics and gynecology, ophthalmology and other specialties sought training to use radioisotopes for specialized techniques, in clinical tests or for clinical research projects.

Since the Atomic Energy Commission agreed, in 1952, to allow certain physicians to use radioactive isotopes in private practice, we have given a preceptorship type of training to many men in practice so that they might become licensed by the Atomic Energy Commission to use radioactive isotopes, or so that they might learn how to use existing radioisotope centers most intelligently for the diagnosis and treatment of their patients.

Recently, every medical student at the University of Michigan Medical School has been assigned to the Clinical Radioisotope Unit as a part of his regular rotation during some part of his junior year.

This text was written primarily to help instruct such persons in the most common clinical uses of radioactive isotopes. The space devoted to each subject is weighted largely according to the popularity of each use. Chapter 10, covering the less commonly used radioisotopes, was added because these substances have been used to some extent in human beings or because it seemed likely to the authors that they might well be adapted to routine use in the future.

Physicians, medical students and technicians have shown us what we must teach and how it must be taught. Dean Ralph Sawyer and Dr. Henry Gombert of the Michigan Memorial Phoenix Project and Dr. Albert Kerlikowske, Director of University Hospital, made our start possible. Dr. C. C. Sturgis, Chairman of the Department of Medicine, and Dr. Fred Hodges, Chairman of the Department of Radiology, promoted the start of the Isotope Unit. Drs. Isadore Lampe and Henry

Gomberg taught the senior author the approach to radioisotope work and a healthy respect for radiation. Dr. F. A. Coller, Chairman of the Department of Surgery, has contributed almost daily in innumerable ways to insure the best possible operation of the unit. Ardath Emmons, Associate Radiation Safety Officer of the University, has been indispensable in his help and instruction in radiation health physics. Dean A. C. Furstenberg has never failed us in our endless requests.

WILLIAM H. BEIERWALTES
PHILIP C. JOHNSON
ARTHUR J. SOLARI

January, 1957

Contents

Chapter 1

CERTAIN PRELIMINARIES	1
Who Should Train?	1
The Medical Student, 1; The Intern and Resident, 1; The Postgraduate in Private Practice, 2.	
Recommendations and Requirements by the Atomic Energy Commission	2
A Minimum Knowledge of Radioactivity	25
The Atom	25
Isotopes	26
Radioactivity	27
Measurement of Radioactivity, 31.	
Half Life	32
Interaction of Radiation with Matter	37
The Energy Unit—The Mev	37
The Alpha Particle	38
The Beta Particle	38
Positrons and Annihilation Radiation	39
Gamma Rays	40
Shielding of Gamma Rays, 40; Inverse Square Law, 41.	
The Roentgen	41
The Rep, RBE, Rem and Rad	42
The Detection of Radiation	42
Gas-Filled Detectors	43
Ionization Chamber, 43; Proportional Counters, 44; Geiger Counters, 44; Self-Quenching Counters (Organic), 46; Bismuth Cathode Geiger-Mueller Tubes, 46.	
Scintillation Counters	47
Scalers, 48; Count Rate Meter, 49.	
Problems in Counting	50
Background, 50; Statistics of Counting, 51; Comparative Counting, 52; Absolute Counting, 54.	

Chapter 2

THYROID PHYSIOLOGY AND RADIOACTIVE IODINE, I ¹³¹	56
Definitions	56
Anatomy of the Thyroid Gland	57
Pituitary-Thyroid Axis	59

I^{131} Absorption, Transport and Excretion	59
Functions of the Thyroid Gland	60
1. Uptake of Iodine and Tyrosine	60
I^{131} Practical Considerations, 62.	
2. Protein Binding of Iodine	67
Mechanism of Action of Antithyroid Drugs, 67; I^{131} Practical Considerations, 68.	
3. Storage of Thyroid Hormone	70
I^{131} Practical Considerations, 70.	
4. Release of Thyroid Hormone	71
I^{131} Practical Considerations, 72.	
Transport, Action and Metabolism of Thyroid Hormone	72
Action of Thyroxine, 72.	

Chapter 3

I^{131} TESTS OF THYROID FUNCTION	78
Thyroid Function versus Patient Function	78
I^{131} Tests of Thyroid Function in General	80
I^{131} Excretion in the Urine, 80; Thyroid I^{131} Uptake, 81; Inorganic or Organically Bound I^{131} Level in Serum, 83.	
The Mechanics of Three Thyroid Function Tests	85
The Two Hour I^{131} Uptake Test	85
Technique, 85; Reporting the Impression, 90.	
The 24 Hour Uptake Test	91
Technique, 91; Helpful Adjuncts to the 24 Hour I^{131} Thyroidal Accumulation Text, 93.	
The One Hour Uptake Test	96

Chapter 4

I^{131} THYROIDECTOMY	99
Treatment of Hyperthyroidism with I^{131}	99
Contraindications to I^{131} Treatment of Hyperthyroidism	99
Carcinogenic Effect, 99; Carcinoma Present in Thyroid, 102; Large Mass of Thyroid, 102; Pregnancy, 103; Severe Hyperthyroidism, 103.	
Indications for Radioiodine Treatment in Hyperthyroidism	103
Previous Thyroidectomy for Hyperthyroidism, 103; Exophthalmic Goiter in Persons over Forty Years of Age, 104; Impractically Long Preoperative Preparation, 104; Hyperthyroidism in the Presence of Well Accepted Contraindications for Surgery, 104; Hyperthyroidism with "Malignant" Exophthalmos at Any Age, 104.	
Principal Reason for I^{131} Treatment	105
Dosage of I^{131}	106
One Dose Method, 106; Fractionation of Dosage, 110; Prediction Tests, 110.	
Unpleasant Effects from I^{131}	111
Thyroiditis, 111; Worsening of Thyrotoxicosis, 111; Hypothyroidism, 111.	
Persistent or Recurrent Hyperthyroidism after I^{131} Treatment ...	112

Goiter in Relation to I^{131}	114
Additional Aspects of I^{131} Thyroidectomy	115
Nodules in Recurrent Exophthalmic Goiter, 115; Thyroidectomies after I^{131} , 116; Pathology, 116; Auricular Fibrillation, 117; Exophthalmos, 118.	
Results to be Expected and Follow-up Care	118
Carcinogenic Effects, 118; Fertility, 118; Radioactivity, 118; Expenses, 118; Thyroiditis, 119; Delay in Effect, 119; Hypothyroidism, 119; Persistent Hyperthyroidism, 119; Persistent Goiter, 120; Exophthalmos, 120; Iodine Reaction, 120; Prognosis, 120.	
Summary: Use of I^{131} in Treatment of Hyperthyroidism	120
Indications and Contraindications, 120; Dose, 121.	
I^{131} Therapy for Angina Pectoris or Intractable Congestive Failure	121
Rationale, 121; Indications, 122; Contraindications, 122; Preparation and Dosage, 123; Results, 124.	
I^{131} Therapy for Intractable Symptoms of Pulmonary Insufficiency	125
Rationale, 125; Indications, 125; Contraindications, 125; Preparation and Dosage, 125; Results, 125.	
I^{131} Therapy for Intractable Parkinsonism	126
Rationale, 126; Indications, 126; Dose, 126; Results, 126.	
I^{131} Therapy for Intermittent Claudication	127
Rationale, 127; Indications, 127.	

Chapter 5

I^{131} IN THE DIAGNOSIS AND TREATMENT OF THYROID NEOPLASMS	131
Diagnosis and Treatment of Goiters Not Yet Proved to Harbor Carcinoma	131
Non-nodular Toxic Goiter	131
Nodular Toxic Goiter	132
Diagnostic Use of I^{131} When Surgery Is Contraindicated, 132; Recurrence after Previous Thyroidectomy, 132.	
Nodular Non-toxic Goiters	132
Solitary Nodules, 132; Non-toxic Multinodular Goiter, 138.	
Recurrent Goiter with Hyperthyroidism	142
Carcinoma, 142; Colloid Goiter, 142; Exophthalmic Goiter, 142; Adenomatous Goiter, 142.	
I^{131} in the Differential Diagnosis of Carcinoma	142
Thyroiditis, 142; Other Forms of Struma, 143.	
Radioiodine Treatment of Proved Carcinoma of the Thyroid Gland	147
Surgical Treatment of Thyroid Carcinoma	147
Roentgen Ray Therapy	149
Indications for I^{131}	149
I^{131} Concentration in Relation to Type of Carcinoma	150
Follicular Carcinoma, 150; Papillary Carcinoma, 150; Papillary and Follicular Carcinoma, 152; More Undifferentiated Types, 155; Primary and Metastatic Types, 156.	
Methods of Determining I^{131} Concentration by Tissue	156
Radioautography, 156; External Gamma Counting, 158; I^{131} Urinary Excretion, 167; Blood I^{131} Level, 168; Indices of Thyroid Function, 168.	
Enhancing Uptake of I^{131} by Thyroid Carcinoma Metastases	168
General Program of Treatment and Follow-up	170

Some Clinical Aspects of Thyroid Cancer Seen in a Radioisotope Unit	170
Age of Patient and Colloid Production of Carcinoma, 170, Presenting Symptom, 172; Patterns Exhibited by Metastases of Thyroid Carcinoma in Lungs, 172.	
Treatment Dosage of I^{131}	174
Toxic Effects of Treatment Dose	175
Local Swelling, 175; Irradiation Sickness, 179; Radiation Sialadenitis, 179; Urinary Tract Effects, 180; Depression of Bone Marrow Function, 180; Ovarian Function, 182.	
Urinary Excretion of I^{131} after Treatment Dose	182
Post-treatment Hypothyroidism	183
Treatment of the Thyroid Carcinoma Patient and Concomitant Desiccated Thyroid Administration, 184.	
Results	185
Pathology of Lesions and Survival after Radioiodine, 185; Deaths, 188; Patients Apparently Well, 188.	

Chapter 6

OTHER CLINICAL USES OF I^{131}	192
Human Serum Albumin (IHSA or RISA) Labeled with Radioactive Iodine	192
Chemical and Physical Properties	192
Pharmacology	192
Mixing with Blood, 192; Mixing with Extravascular Pools, 193; The Metabolic Degradation of the Isotopically Labeled Protein, 193.	
Localization of IHSA	194
Localization in Tumors, 194; Localization in Ascitic Fluid, 194; Edema Fluid, 194.	
Radiation Hazard from IHSA	195
I^{131} IHSA Blood Volume Determination	195
Other Physiologic Considerations, 195; Technique of I^{131} IHSA Blood Volume, 198; Variations in Blood Volume, 203.	
Other Uses of I^{131} -Labeled Human Serum Albumin (IHSA or RISA) 203	
Brain Tumor Localization, 203; Circulation Time, Dilution Curve and Cardiac Output, 210; Radiocardiography, 217; Saphenous Circulation Time, 220; Peripheral Circulation, 220; Myeloscintigram, 223; Diagnosis of Carcinoma Metastatic to Liver, 226; Diagnosis of Pancreatic Insufficiency, 228.	
Other Uses of I^{131}	231
Diagnosis of Gallbladder Disease	231
Rationale, 231; Technique, 231; Results, 231.	
Liver Function Test	231
Rationale, 231; Technique, 234; Interpretation, 234.	

Chapter 7

RADIOACTIVE PHOSPHORUS (P^{32})	240
Pharmacology	240
Physical Characteristics, 240; Rationale of Use, 240; Absorption and Excretion, 241.	

Diagnostic Uses of P³²	241
Brain Tumor Localization	241
Localization, 241; Technique, 241; Uses, 241; Tumor Type, 242; Time Interval, 242; Age of Patient, 243.	
Eye Tumor Localization	243
Rationale, 243; Technique, 243; Localization of Posterior Ocular Tumors, 244; Interpretation of Results, 244; Uses, 245.	
Determination of Viability of Tissue	246
Determination of Cutaneous Burn Depth, 246; Determination of Circulation in Tubed Pedicle Flaps, 246.	
Blood Volume Determination	247
Rationale, 247; Technique, 247; Normal Values, 248; Clinical Utility, 248.	
Therapeutic Use of Radioactive Phosphorus	248
Radioactive Phosphorus in Polycythemia Vera	248
Therapeutic Considerations, 248; A Therapeutic Regimen, 250; Duration of Remissions Produced and Comparison with Other Forms of Therapy, 251.	
Radioactive Phosphorus in Leukemia	251
Selection of Patients, 251; Dosage, 251; Survival, 251; Chronic Granulocytic Leukemia, 252; Chronic Lymphatic Leukemia, 253.	
Radioactive Chromic Phosphate	253
Chromic Phosphate vs. Gold	253
Radiation, 253; Half Life, 253; Distribution, 253.	
Method of Preparation	254
Technique	255

Chapter 8

RADIOACTIVE GOLD	257
Pharmacology	257
Fate after Intraperitoneal or Intrapleural Injection for Treatment, 257.	
Intracavitary Use	258
Indications	258
Method of Administration	259
Equipment, 259; Technique, 259.	
Dosage	261
Mode of Action, 261.	
Reactions to Au¹⁹⁸ in Therapy	261
Symptoms, 261; Bone Marrow Depression, 262; Liver Function, 262.	
Therapeutic Results	262
Direct Tumor Injection	263
Rationale, 263; Equipment, 263; Technique, 263; Dosimetry in Injection Technique, 264; Results, 264.	
Injection into Prostatic Carcinoma	265
Selection of Patients, 265; Rationale and Distribution of Injected Gold, 265; Technique, 265; Reactions, 266; Results, 266.	
Injection for Other Pelvic Cancer	266
Rationale, 266; Technique, 266; Reactions, 267; Results, 267.	
Treatment of Carcinoma of Lung	267
Rationale, 267; Results, 267.	

Intravenous Administration of Au ¹⁹⁸	268
Distribution	268
Particle Size, 268; Tissues and Organs, 268.	
Toxicity	269
Liver, 269; Blood, 269.	
For Treatment of Chronic Granulocytic Leukemia	269
For Treatment of Carcinoma in Liver	270
Intrathecal Injection	270
Rationale, 270; Toxicity, 270; Distribution, 270; Results, 270.	

Chapter 9

RADIOACTIVE CHROMIUM, CR ⁵¹ , COBALT, CO ⁶⁰ , AND IRON, FE ⁵⁵ AND FE ⁵⁹	273
Radioactive Chromium	273
Pharmacology of Cr ⁵¹	273
Physical Characteristics, 273; Biochemistry, 273; Distribution and Excretion in Man, 274.	
Blood Volume Determinations	275
Rationale, 275; Technique, 275.	
Use of Cr ⁵¹ RBC Labeling for Study of RBC Survival in Normal and Disease States	280
Rationale, 280; Technique, 281; Results and Interpretation, 281.	
Cr ⁵¹ Red Blood Cell Half Life	282
Cr ⁵¹ Quantitation of Blood Loss Through Gastrointestinal Bleeding	283
Rationale, 283.	
Use of Other Radioisotopes in the Differential Diagnosis of Anemia	284
Use of Radioactive Cobalt (Co ⁶⁰) Labeled Vitamin B ₁₂ to Diagnose Pernicious Anemia	284
Rationale, 284; Technique, 284.	
Radioactive Iron, Fe ⁵⁹	288
Physical Characteristics, 288; Rationale of Use in Diagnosis of Anemias, 288; Technique for Plasma Clearance, Plasma Iron Turnover and Iron Per Cent Utilization Curve, 290.	

Chapter 10

OTHER LESS COMMONLY USED RADIOACTIVE ISOTOPES	296
Radioactive Arsenic, As ⁷⁴	296
Pharmacology, 296; Rationale of Use in Brain Tumor Detec- tion, 297; Technique, 298; Results, 298.	
Astatine, At ²¹¹	298
Pharmacology, 298; Application, 299.	
Boron, B ¹⁰	299
Rationale, 299; Technique, 300; Toxicity, 300; Results, 300.	
Radioactive Bromine, Br ⁸² (and Chlorine, Cl ³⁶)	301
Radiobromine, 301; Radiochloride, 301.	
Estimation of Total Body Chloride in Man by Radiobromide Dilution	301
Technique, 301; Results, 302; Radiation Hazard, 302.	
Radioactive Calcium and Strontium	302
Pharmacology, 302; Clinical Studies, 303.	

Radioactive Carbon, C ¹⁴	303
Radioactive Cerium	304
Radioactive Cesium	304
Radioactive Chlorine	304
Radioactive Cobalt	304
For Teletherapy, 304.	
Radioactive Copper, Cu ⁶⁴	305
Radioactive Fluorine, F ¹⁸	306
Radioactive Gallium, Ga ⁷²	306
Radioactive Germanium, Ge ⁷¹	307
Hydrogen ³ (Tritium)	307
Method, 307; Toxicity, 308; Results, 308.	
Radioactive Iridium, Ir ¹⁹²	308
Radioactive Krypton (and Other Inert Gases)	309
Inert Gas Exchange, 309; Study of Peripheral Circulation, 309;	
Suppression of Gastric Acidity, 310.	
Radioactive Lanthanum, La ¹⁴⁰	310
Radioactive Lead, Pb ²¹⁰	310
Radioactive Manganese, Mn ⁵²	311
Radiomercury, Hg ²⁰³	311
Radioactive Potassium, K ⁴² (and Sodium, Na ^{22, 24})	312
Method of K ⁴² Determination of Exchangeable Potassium, 312.	
Radioactive Sodium	314
Radiocardiogram and Peripheral Circulation Studies, 314; Total	
Exchangeable Sodium, 315.	
Simultaneous Determination of Both Na ²⁴ and K ⁴²	317
Exchangeable Body Sodium Determination with Sodium	318
Rubidium, Rb ⁸⁶	319
Radioactive Silver, Ag ^{110, 111}	320
Use in Liver Function Test, 320.	
Radioactive Sodium, Na ^{22, 24}	320
Radioactive Strontium, Sr ^{89, 90}	320
Radioactive Sulfur, S ³⁵	320
Determination of Extracellular Fluid Volume, 321; Study of	
Tumors, 322; Protein Metabolism, 322.	
Thorium X (88 Ra ²²⁴)	322
Radioactive Thallium, Tl ²⁰⁴	322
Uranium ²³³	323
Yttrium ^{90, 91}	323
Distribution, 323.	
Radioactive Zinc, Zn ⁶⁵	324

Chapter 11

BIOLOGIC EFFECTS OF RADIATION	329
Acute Penetrating Radiation Syndrome in Man	329
Hyperacute Reaction, 329; Initial Reaction, 330; Acute to Sub-	
acute Reaction, 330; Treatment of Acute Penetrating Radiation	
Syndrome, 331.	
The Chronic Radiation Syndrome	333-
Relative Radiosensitivity of Various Human Organs	335
Cytochemistry of Radiation Injury	335

Radiosensitivity of Cells	336
Changes Observed in Tissues and Organs, 337; Genetic Effects, 343.	

Chapter 12

HEALTH PHYSICS IN THE CLINICAL USE OF RADIOISOTOPES	345
Types of Radiation Hazards	345
External Hazards	346
Tolerance Dose, 346; Protection from External Radiation, 346.	
Internal Radiation Hazards	358
Comparison of External and Internal Hazards, 359; Calculation of Radiation Exposure from Internal Emitters, 359; Tolerance Levels, 361; Protection from Internal Hazards, 361; Hazards to Experiments, 362.	
Radioactive Waste Disposal	363
Storage, 363; Liquid Waste Disposal, 363.	
Contamination Control and Removal	365
Skin Contamination, 365; Clothing and Bedding Contamination, 366; Detecting Instrument Contamination, 367; Glassware Contamination, 367; Miscellaneous Equipment Contamination, 368; Floors and Bench Tops, 368; Most Common Laboratory Accidents, 368.	
Twelve Unsafe Practices in Handling Radioisotopes	369

Chapter 13

INSTRUMENTATION IN THE CLINICAL RADIOISOTOPE UNIT ...	371
Scalers	371
Mechanical Register, 371; Scaling Circuit, 372; Input Circuit, 373; High Voltage Supply, 373; Timer, 374.	
Count Rate Meters	376
External Recorder, 376; Special Rate Meters, 376.	
Gas-Filled Detectors	377
Gas Flow Detectors, 379; Window Flow Counters, 379; 4π Counters, 380; Bernstein-Ballantine Counter, 380.	
Solid Counters	380
Scintillation Counters, 380.	
Linear Amplifiers	383
Pulse Height Analyzer	384
Spectrometers	385
The Medical Scintillation Spectrometer, 387.	
Coincidence and Anticoincidence Circuits	388
Ionization Chambers	388
Determination of Operating Voltage	390
Calibration of Counters	392
Calibration of Scintillation Well-Type Counter with I^{131} , 392;	
Calibration of a Thin-Window Geiger Tube for P^{32} or I^{131} , 393;	
Calibration with a Radium D and E Source, 393; Calibration by Coincidence Counting, 395.	
Calibration of the Electroscope	396

Suggested Equipment for an Isotope Unit	398
Thyroid Function Tests, 398; I^{131} Therapy—Less than 30 mc., 398; I^{131} Therapy for Carcinoma, 398; Blood Volumes: HSA or Cr^{51} , 398; P^{32} Diagnosis and Therapy, 399; Co^{60} —Schilling Test, 399; Au^{198} Therapy, 399.	
Costs and Servicing	399

Chapter 14

STARTING AND MANAGING A CLINICAL RADIOISOTOPE UNIT ..	401
The Physician	401
The Hospital	401
Superintendent, 401; Hospital Employees, 401.	
Requesting Tests or Treatment Procedures	406
Space and Equipment	408
Space	408
Basic Requirements, 408; Where to Locate, 408; Delivery, Venting and Plumbing, 409.	
Small Hospitals and Private Practitioners	409
Larger Clinical Radioisotope Unit Facilities	411
Expenses and Income	413
Interested Colleagues	415
The Future	416
Physician or Physicist	419
Further Training	420

Appendices

APPENDIX A. STATISTICS OF COUNTING	421
APPENDIX B. DECAY TABLES OF RADIOISOTOPES	427
APPENDIX C. RADIOAUTOGRAPHY OF THYROID SECTIONS	429
APPENDIX D. SHIELD THICKNESS FOR LABORATORY SOURCES ..	432
APPENDIX E. COMPILATIONS OF NUCLEAR DATA	434
APPENDIX F. FORMAL CLINICAL RADIOISOTOPES TRAINING COURSES	435
APPENDIX G. COMMERCIAL SUPPLIERS OF ISOTOPE-LABELED COMPOUNDS	437
INDEX	439

Certain Preliminaries

WHO SHOULD TRAIN?

WHO SHOULD receive training to diagnose and treat patients with radioactive isotopes? When in the physician's career should this training be acquired? How should one acquire this training?

On February 7 and 8, 1954, a Conference on Training in the Use of Radioactive Isotopes, sponsored by Northwestern University Medical School and Argonne National Laboratory, was held in Chicago to urge certain interested persons to crystallize their thinking on these problems. Our opinions coincide with the conclusions derived from this conference.

1. **The Medical Student.** The medical student is required to take chemistry and physics in undergraduate school. When he enters medical school, a separate course on radiation biology or clinical techniques should not be taught, both because of curriculum difficulties and because this material can be pertinently presented in relation to material included in existing courses. On the other hand, coverage of certain fundamental topics in this field should not be left to chance. Inclusion of such topics in specific courses should be recommended by the curriculum committees.

Instruction should be given in the freshman year on properties of radiation, principles of radiation detection and measurement, and interaction of radiation and matter. This material, presented in lecture and demonstration, should be included in either 'biological chemistry or physiology, depending upon which subject is presented first in the curriculum. As students are now taught to think in chemical terms of the structure and interrelationships of matter, they should also be encouraged to regard structure and function from a physical point of view. The effect of radiation on tissue might be taught in the second year in pharmacology or pathology. Instruction on radiation hazards and protection should be included in the curriculum, possibly in the junior year, as a part of the course work either in radiology or in public health and preventive medicine. The application of radioisotopes in diagnosis and therapy would be left entirely to the clinical departments as to what and how much to include.

2. **The Intern and Resident.** Current opinion agrees that radioactive isotopes should be a tool for the use of the skilled clinician in diag-

nosis and treatment. It is suggested, therefore, that the period of radioisotope training might best be presented at the end of two or three years of specialty training. The major quantity of radioisotopes used in clinical medicine today are administered by internists, radiologists and surgeons. Pathology may soon include training in radioisotopes as part of clinical laboratory pathology. We have made rotation through the Clinical Radioisotope Unit available to all residents in University Hospital to give them a broader knowledge of modern medicine, to prepare them to be relatively well informed members of their community in respect to questions of atomic warfare, civil defense programs and hazards which might arise or be alleged to arise from industrial use of artificial radioactivity, and, most important, to equip them for the possibility that they may be needed to head a clinical radioisotope laboratory in a university hospital or a leading hospital in a large community.

3. **The Postgraduate in Private Practice.** Physicians in private practice generally request training in a clinical isotope unit for one of two reasons. The specialist usually wants to learn how to handle a certain radioactive isotope in his practice as a specialized tool in his daily work. The general practitioner, on the other hand, desires information on the indications for the use of all clinical radioisotopes in his patients, how to prepare his patients for these isotopes, and how to handle his patients after the isotopes have been administered to his patients. This latter type of instruction should be available to any physician to keep him informed on the utility of this new development in modern medicine.

RECOMMENDATIONS AND REQUIREMENTS BY THE ATOMIC ENERGY COMMISSION

The Atomic Energy Commission has made several specific recommendations and requirements to be met by the person who wishes to use radioisotopes in clinical medicine. These statements are reproduced *in toto* as follows.

THE MEDICAL USE OF RADIOISOTOPES

Recommendations and Requirements by the Atomic Energy Commission

I. INTRODUCTION

The present procedures of the Atomic Energy Commission for the allocation of radioisotopes for medical research, diagnosis and therapy are set forth in this announcement. The recommendations for minimum clinical radioisotope training and experience for use of radioisotopes in human subjects have been established in advisement with the Subcommittee on Human Applications of the Atomic Energy Commission's General Advisory Committee on Isotope Distribution.

These recommendations are designed to provide guidelines for physicians and typify the nature rather than the precise extent of the desirable clinical radioisotope experience. For special situa-

tions, other experience may serve in lieu of the particular recommendations set forth in this announcement.

II. ADMINISTRATIVE PROCEDURE FOR RADIOISOTOPE PROCUREMENT

A. APPLICATION

A medical institution or a physician in an individual medical practice desiring to obtain radioisotopes, forwards to the Isotopes Extension*, Form AEC-313, "Application for Byproduct Material Licenses," and Supplement A, (Form AEC-313-a). If the radioisotopes are to be obtained as sealed sources (such as Cobalt 60 for teletherapy units or Strontium 90 for medical eye applicator), the applicant should complete the basic form (Form AEC-313) and Supplement B (Form AEC-313-b). These forms should be completed in accordance with the instructions attached thereto. Applications for use of radioisotopes in human subjects in an INSTITUTIONAL MEDICAL PROGRAM should be supported by the special information described under Section III, Page 4, Section IV, Page 6 and Section V, Page 7 of this announcement. For such use by a physician in his INDIVIDUAL MEDICAL PRACTICE the application should be supported by the special information described under Section III, Page 4, Section VI, Page 11 and Section VII, Page 13.

In considering such applications, the Atomic Energy Commission is concerned primarily with matters of radiological health safety. Toward this end the Commission seeks to determine if the applicant has equipment and facilities appropriate to the proposed use and whether the physician is trained in basic principles of radioactivity and has specific experience in the use of radioisotopes in the clinical situations being proposed. The information is indicated by the applicant on his application form and the supplementary sheets attached thereto.

B. LICENSE

Upon favorable review of the application (See NOTE below), Form AEC-374, "Byproduct Material License," is issued. This license permits the holder to procure radioisotopes in accordance with the conditions stated on the application and license forms and in Title 10 of the Code of Federal Regulations.

NOTE. The Isotopes Extension normally reviews applications proposing new or nonroutine medical uses of radioisotopes in collaboration with the Advisory Subcommittee on Human Applications. This review usually requires four weeks for completion.

C. TYPES OF CLINICAL RADIOISOTOPE PROGRAMS

The recommendations and requirements established by the Atomic Energy Commission for the clinical use of radioisotopes are designed to provide for two types of medical radioisotope programs. These are defined as follows:

1. Institutional Medical Radioisotope Program

Clinical radioisotope programs established by a medical institution and carried out under the guidance of a medical isotopes committee (See recommendations for membership and duties of a medical isotopes committee in Section IV, A. Page 6) are designated as "Institutional use." Licenses for institutional use require that the physician(s) named on the license form supervise the conduct of

* Allocations Branch, Isotopes Extension, Division of Civilian Application, U.S. Atomic Energy Commission, P. O. Box E, Oak Ridge, Tennessee.